Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260955 | 0.82 | PTAFR (0.44) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL12362314 | 0.81 | HDAC8 (0.39) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL12362300 | 0.81 | HDAC8 (0.37) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL12362301 | 0.78 | PTAFR (0.36) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL12264975 | 0.77 | HDAC8 (0.38) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL18927873 | 0.75 | PTAFR (0.36) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL18928155 | 0.75 | PTAFR (0.36) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL1655758 | 0.74 | PTAFR (0.41) | PTAFR | |
| SCHEMBL1655948 | 0.74 | PTGS2 (0.35) | PTAFRHDAC8CA1CA2CA4 | |
| SCHEMBL4539391 | 0.74 | PTAFR (0.35) | PTAFRHDAC8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859572-B2 | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | PTAFR 1026/4885HDAC8 1199/4885CA1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.